https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-03-21 10:18:332026-09-21 14:06:27Astex Pharmaceuticals Announces March 27th Analyst and Investor Day Agenda
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-03-06 10:22:242026-09-21 14:07:19Eisai Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Dacogen® (decitabine) for Injection sNDA in Acute Myeloid Leukemia
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-02-28 11:47:452026-09-21 14:07:12Astex Pharmaceuticals to Announce 2011 Fourth Quarter and Year-End Financial Results on March 5, 2012
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-02-16 11:49:492026-09-21 14:08:08Astex Pharmaceuticals to Host Annual Analyst and Investor Day on March 27, 2012
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-02-09 11:52:452026-09-21 14:08:15FDA’s Oncologic Drugs Advisory Committee (ODAC) Votes to not Support Benefit/Risk Profile of DACOGEN® (decitabine) in Acute Myeloid Leukemia
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-01-16 11:55:402026-09-21 14:08:22Astex Announces Early Transfer of Epigenetics Project to GSK